Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRO NYSE:KDMN NASDAQ:MGNX NASDAQ:MGTA NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$45.22-2.1%$48.19$21.34▼$58.40$3.62B-0.241.38 million shs2.77 million shsKDMNKadmon$9.50$9.50$3.19▼$9.50$1.70BN/A5.11 million shs1,052 shsMGNXMacroGenics$1.62-6.4%$1.63$0.99▼$5.10$102.40M1.63924,822 shs923,220 shsMGTAMagenta Therapeutics$0.70-7.7%$0.53$0.32▼$2.07$42.44M2.12848,835 shs376,000 shsVKTXViking Therapeutics$25.40-2.5%$30.57$18.92▼$81.73$2.86B0.734.84 million shs7.27 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics+9.53%+2.83%-2.94%-14.76%+71.36%KDMNKadmon0.00%0.00%0.00%0.00%0.00%MGNXMacroGenics+13.07%+4.85%+16.11%+32.06%-47.58%MGTAMagenta Therapeutics0.00%0.00%0.00%0.00%0.00%VKTXViking Therapeutics+12.78%+1.17%+6.90%+0.12%-59.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$45.22-2.1%$48.19$21.34▼$58.40$3.62B-0.241.38 million shs2.77 million shsKDMNKadmon$9.50$9.50$3.19▼$9.50$1.70BN/A5.11 million shs1,052 shsMGNXMacroGenics$1.62-6.4%$1.63$0.99▼$5.10$102.40M1.63924,822 shs923,220 shsMGTAMagenta Therapeutics$0.70-7.7%$0.53$0.32▼$2.07$42.44M2.12848,835 shs376,000 shsVKTXViking Therapeutics$25.40-2.5%$30.57$18.92▼$81.73$2.86B0.734.84 million shs7.27 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics+9.53%+2.83%-2.94%-14.76%+71.36%KDMNKadmon0.00%0.00%0.00%0.00%0.00%MGNXMacroGenics+13.07%+4.85%+16.11%+32.06%-47.58%MGTAMagenta Therapeutics0.00%0.00%0.00%0.00%0.00%VKTXViking Therapeutics+12.78%+1.17%+6.90%+0.12%-59.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$81.1479.56% UpsideKDMNKadmon 0.00N/AN/AN/AMGNXMacroGenics 2.50Moderate Buy$3.60122.91% UpsideMGTAMagenta Therapeutics 0.00N/AN/AN/AVKTXViking Therapeutics 3.00Buy$87.50244.57% UpsideCurrent Analyst Ratings BreakdownLatest MGNX, KDMN, VKTX, AKRO, and MGTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/17/2025MGNXMacroGenicsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$3.009/16/2025MGNXMacroGenicsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/4/2025AKROAkero TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$72.008/19/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.008/15/2025MGNXMacroGenicsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$8.00 ➝ $5.008/4/2025AKROAkero TherapeuticsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy8/4/2025AKROAkero TherapeuticsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$76.007/24/2025VKTXViking TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetStrong-Buy$125.00 ➝ $122.007/24/2025VKTXViking TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$31.00 ➝ $38.006/25/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/AKDMNKadmonN/AN/AN/AN/AN/AN/AMGNXMacroGenics$149.96M0.68N/AN/A$1.85 per share0.87MGTAMagenta TherapeuticsN/AN/AN/AN/A$1.23 per shareN/AVKTXViking TherapeuticsN/AN/AN/AN/A$7.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$2.00N/AN/AN/AN/A-15.84%-14.59%11/14/2025 (Estimated)KDMNKadmonN/AN/A0.00∞N/AN/AN/AN/AN/AMGNXMacroGenics-$66.97M-$0.57N/AN/AN/A-21.99%-40.24%-14.62%11/4/2025 (Estimated)MGTAMagenta Therapeutics-$76.46MN/A0.00∞N/AN/A-70.88%-57.27%N/AVKTXViking Therapeutics-$109.96M-$1.53N/AN/AN/AN/A-19.98%-19.38%10/22/2025 (Estimated)Latest MGNX, KDMN, VKTX, AKRO, and MGTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MGNXMacroGenics-$0.59-$0.57+$0.02-$0.57$28.06 million$22.24 million8/8/2025Q2 2025AKROAkero Therapeutics-$0.97-$0.86+$0.11-$0.86N/AN/A7/23/2025Q2 2025VKTXViking Therapeutics-$0.44-$0.58-$0.14-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/AKDMNKadmonN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/AMGTAMagenta TherapeuticsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0212.6612.66KDMNKadmonN/AN/AN/AMGNXMacroGenicsN/A5.265.02MGTAMagenta TherapeuticsN/A19.4919.49VKTXViking TherapeuticsN/A25.8625.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/AKDMNKadmonN/AMGNXMacroGenics96.89%MGTAMagenta Therapeutics47.53%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%KDMNKadmonN/AMGNXMacroGenics13.00%MGTAMagenta Therapeutics15.18%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.99 million74.33 millionOptionableKDMNKadmonN/A178.52 millionN/AOptionableMGNXMacroGenics43063.21 million54.99 millionOptionableMGTAMagenta Therapeutics6760.67 million51.46 millionNot OptionableVKTXViking Therapeutics20112.45 million107.84 millionOptionableMGNX, KDMN, VKTX, AKRO, and MGTA HeadlinesRecent News About These CompaniesViking Therapeutics (NASDAQ:VKTX) Trading Up 10.6% - Should You Buy?1 hour ago | marketbeat.comPrediction: Viking Therapeutics Stock Will Double in Value Within the Next 12 MonthsSeptember 19 at 4:40 AM | fool.comViking Therapeutics, Inc. $VKTX Shares Sold by Harbor Capital Advisors Inc.September 18 at 3:58 AM | marketbeat.comViking Therapeutics, Inc. (VKTX): A Bull Case TheorySeptember 18 at 2:12 AM | finance.yahoo.comBiotech Breakouts: 3 Stocks With Massive Upside Potential (VKTX)...September 17 at 6:22 PM | marketbeat.comWesbanco Bank Inc. Has $1.38 Million Holdings in Viking Therapeutics, Inc. $VKTXSeptember 17 at 3:55 AM | marketbeat.comViking Therapeutics, Inc. $VKTX Position Reduced by Voya Investment Management LLCSeptember 17 at 3:27 AM | marketbeat.comViking Therapeutics, Inc. (VKTX): A Bull Case Theory September 16 at 2:31 PM | insidermonkey.comAMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?September 16 at 2:01 PM | zacks.comViking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to KnowSeptember 15, 2025 | zacks.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Buy" by BrokeragesSeptember 15, 2025 | marketbeat.comWoodline Partners LP Acquires 207,784 Shares of Viking Therapeutics, Inc. $VKTXSeptember 14, 2025 | marketbeat.comWealth Management Associates Inc. Purchases Shares of 9,975 Viking Therapeutics, Inc. $VKTXSeptember 13, 2025 | marketbeat.comAlliancebernstein L.P. Decreases Position in Viking Therapeutics, Inc. $VKTXSeptember 12, 2025 | marketbeat.comViking Therapeutics (VKTX): Reassessing Valuation After Clinical Trial Setback and Weak EarningsSeptember 11, 2025 | finance.yahoo.comWhere Does VKTX Stock Stand After the Obesity Pill Setback?September 11, 2025 | zacks.comWall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?September 9, 2025 | zacks.com5 Stocks Poised to DOUBLE Your Money by 2027September 9, 2025 | 247wallst.comViking Therapeutics, Inc. (VKTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.comViking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to NoteSeptember 8, 2025 | zacks.comViking Therapeutics, Inc. $VKTX Shares Acquired by Curi RMB Capital LLCSeptember 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Zillow Group Approaching Key Technical Levels: Is It Time to Buy?By Dan Schmidt | August 23, 2025Biotech Breakouts: 3 Stocks With Massive Upside PotentialBy Chris Markoch | September 17, 2025MGNX, KDMN, VKTX, AKRO, and MGTA Company DescriptionsAkero Therapeutics NASDAQ:AKRO$45.22 -0.98 (-2.12%) Closing price 04:00 PM EasternExtended Trading$46.61 +1.39 (+3.07%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Kadmon NYSE:KDMNKadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.MacroGenics NASDAQ:MGNX$1.62 -0.11 (-6.36%) Closing price 04:00 PM EasternExtended Trading$1.62 +0.00 (+0.06%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Magenta Therapeutics NASDAQ:MGTAMagenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Viking Therapeutics NASDAQ:VKTX$25.40 -0.64 (-2.46%) Closing price 04:00 PM EasternExtended Trading$25.59 +0.19 (+0.75%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Joby's Stock Is Quiet, But Its Commercial Engine Is In Overdrive NIO's New Dawn: Why Wall Street's Bullish Turn Signals a Comeback Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
